JP2009519944A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519944A5
JP2009519944A5 JP2008545835A JP2008545835A JP2009519944A5 JP 2009519944 A5 JP2009519944 A5 JP 2009519944A5 JP 2008545835 A JP2008545835 A JP 2008545835A JP 2008545835 A JP2008545835 A JP 2008545835A JP 2009519944 A5 JP2009519944 A5 JP 2009519944A5
Authority
JP
Japan
Prior art keywords
antibody
dll4
antagonist
use according
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008545835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519944A (ja
JP5489465B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/047848 external-priority patent/WO2007070671A2/en
Publication of JP2009519944A publication Critical patent/JP2009519944A/ja
Publication of JP2009519944A5 publication Critical patent/JP2009519944A5/ja
Application granted granted Critical
Publication of JP5489465B2 publication Critical patent/JP5489465B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008545835A 2005-12-16 2006-12-15 Dll4アンタゴニストによって腫瘍増殖を阻害する治療方法 Expired - Fee Related JP5489465B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US75117305P 2005-12-16 2005-12-16
US60/751,173 2005-12-16
US77127606P 2006-02-08 2006-02-08
US60/771,276 2006-02-08
US78845606P 2006-03-31 2006-03-31
US60/788,456 2006-03-31
US83054306P 2006-07-12 2006-07-12
US60/830,543 2006-07-12
PCT/US2006/047848 WO2007070671A2 (en) 2005-12-16 2006-12-15 Therapeutic methods for inhibiting tumor growth with dll4 antagonists

Publications (3)

Publication Number Publication Date
JP2009519944A JP2009519944A (ja) 2009-05-21
JP2009519944A5 true JP2009519944A5 (cg-RX-API-DMAC10.html) 2013-02-14
JP5489465B2 JP5489465B2 (ja) 2014-05-14

Family

ID=38163537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545835A Expired - Fee Related JP5489465B2 (ja) 2005-12-16 2006-12-15 Dll4アンタゴニストによって腫瘍増殖を阻害する治療方法

Country Status (12)

Country Link
US (1) US20080107648A1 (cg-RX-API-DMAC10.html)
EP (1) EP1962895B2 (cg-RX-API-DMAC10.html)
JP (1) JP5489465B2 (cg-RX-API-DMAC10.html)
AU (1) AU2006326417B2 (cg-RX-API-DMAC10.html)
CA (1) CA2630839C (cg-RX-API-DMAC10.html)
DK (1) DK1962895T3 (cg-RX-API-DMAC10.html)
ES (1) ES2400666T5 (cg-RX-API-DMAC10.html)
IL (1) IL191810A (cg-RX-API-DMAC10.html)
NZ (1) NZ568739A (cg-RX-API-DMAC10.html)
PL (1) PL1962895T3 (cg-RX-API-DMAC10.html)
PT (1) PT1962895E (cg-RX-API-DMAC10.html)
WO (1) WO2007070671A2 (cg-RX-API-DMAC10.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
JP2009539870A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
HRP20160082T1 (hr) * 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
EP2081962B1 (en) 2006-10-19 2018-10-03 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
JP5478254B2 (ja) 2006-10-19 2014-04-23 ジェネンテック, インコーポレイテッド 抗ノッチ3アゴニスト抗体とノッチ3関連疾患の治療におけるその使用
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2099827B1 (en) 2006-12-18 2018-11-21 Genentech, Inc. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP2120996A2 (en) * 2006-12-20 2009-11-25 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
EP2125013A4 (en) * 2007-01-26 2010-04-07 Bioinvent Int Ab DLL4 SIGNALING INHIBITOR AND ITS USES
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
US7544476B1 (en) * 2008-07-11 2009-06-09 Aveo Pharmaceuticals, Inc. Identifying cancers sensitive to treatment with inhibitors of notch signaling
CN102264763B (zh) * 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
MX2011002928A (es) * 2008-10-01 2011-04-11 Genentech Inc Anticuerpos anti-notch2 y metodos de uso.
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以dll4拮抗劑與化學治療劑治療癌症之方法
CA2771575A1 (en) * 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
UY32917A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
US20110165162A1 (en) * 2009-12-01 2011-07-07 Oncomed Pharmaceuticals, Inc. Methods for Treating Cancers Comprising K-ras Mutations
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Vegf/dll4結合劑類及彼等之用途
US20140093498A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以dll4拮抗劑治療卵巢癌之方法
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
WO2023063842A1 (ru) * 2021-10-12 2023-04-20 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
DE69829891T2 (de) † 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
JP4171528B2 (ja) * 1997-05-14 2008-10-22 旭化成株式会社 新規な分化抑制剤
EP1179541B1 (en) † 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN101433715B (zh) † 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20050089518A1 (en) * 2001-12-07 2005-04-28 Clarke Michael F. Prospective identification and characterization of breast cancer stem cells
JP2005526701A (ja) * 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
EP1537145A1 (en) 2002-09-10 2005-06-08 Lorantis Limited Pharmaceutical compositions and medical treatments comprising notch ligand proteins
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
EP1928486A2 (en) * 2005-09-01 2008-06-11 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
JP2009539870A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
AU2007319672B2 (en) † 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same

Similar Documents

Publication Publication Date Title
JP2023002706A (ja) 抗pdl1抗体、活性化可能抗pdl1抗体、およびその使用方法
JP2021006044A (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
EP2773669B1 (en) Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
JP2020513809A5 (cg-RX-API-DMAC10.html)
JP2015120706A5 (cg-RX-API-DMAC10.html)
JP2014518615A5 (cg-RX-API-DMAC10.html)
JP2019216719A (ja) Cd47に対するヒト化及びキメラモノクローナル抗体
WO2007070671A3 (en) Therapeutic methods for inhibiting tumor growth with dll4 antagonists
CN106659779A (zh) 双特异性四价抗体及其制造和使用方法
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
HRP20191341T1 (hr) Protutijela koja vežu ljudski cgrp receptor
JP2015511962A5 (cg-RX-API-DMAC10.html)
JP2012509881A5 (cg-RX-API-DMAC10.html)
JP2010533498A5 (cg-RX-API-DMAC10.html)
JP2017509323A5 (cg-RX-API-DMAC10.html)
JP2013523184A5 (cg-RX-API-DMAC10.html)
RU2015126533A (ru) Анти-cd47 антитела и способы их применения
JP2020536492A5 (cg-RX-API-DMAC10.html)
WO2017060322A3 (en) Ptefb-inhibitor-adc
TW201609805A (zh) 結合egfr及met之多功能抗體
JP2009522316A5 (cg-RX-API-DMAC10.html)
CN111032689A (zh) 抗爱帕琳肽抗体及其用途
CN113853388A (zh) 抗-egfrviii抗体及其抗原结合片段
JP2005535562A5 (cg-RX-API-DMAC10.html)
CN114423789A (zh) 针对间皮素的抗体及其用途